GO
Loading...

Medicine

More

  • Vivus' Mr. Wilson Goes To Washington Monday, 26 Oct 2009 | 2:26 PM ET

    Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.

  • Eli Lilly's Economic Measuring Stick Wednesday, 21 Oct 2009 | 12:12 PM ET

    The folks at Eli Lilly probably cringe every time I go here, but the company this morning reported that third quarter U.S. sales of the erectile dysfunction drug Cialis sprung 13 percent to nearly $159 million.

  • Pfizer Fills Its Pipe Tuesday, 20 Oct 2009 | 5:15 PM ET

    One of the things we learned in Pfizer's earnings press release and on the conference call today is that since the start of 2008 the company has eliminated 11,200 positions. And now that the world's biggest pharmaceutical firm has gotten even bigger by swallowing Wyeth, it's going to let go even more people to help wring out about $4 billion in annual expenses by 2012.

  • Amgen's Party Pooper Monday, 19 Oct 2009 | 12:27 PM ET
    Amgen

    In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.

  • H1N1 In The Heartland Thursday, 15 Oct 2009 | 4:21 PM ET

    Notes from the front lines of the battle against H1N1. So, I've spent part of yesterday and most of today at the University of Kansas Hospital covering the first H1N1 flu shots being administered.

  • H1N1 Shots Are Here: Sign Me Up Wednesday, 14 Oct 2009 | 12:31 PM ET

    This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.

  • Novartis Vindicates Vanda Tuesday, 13 Oct 2009 | 3:58 PM ET
    Novartis Headquarters

    Vanda Pharmaceuticals may go down in industry history as one of the most remarkable turnaround stories.

  • A New Direction For Dendreon? Monday, 12 Oct 2009 | 1:15 PM ET

    Dendreon is growing in more ways than one. At a time when so many drug companies are letting people go, Dendreon is on a hiring binge to ramp up for the anticipated launch of its prostate cancer drug Provenge. But it's also expanding its board of directors.

  • IMS Health Writes A New Script Thursday, 8 Oct 2009 | 3:19 PM ET

    With $137 billion worth of brand name drugs going generic over the next several years, the recession and the looming threat of healthcare reform a lot of people have been running scared about what it all means for pharma. So, surprise, surprise! This morning IMS Health, which closely monitors the industry, came out with its annual forecast and it now says the American drug market is going to grow this year instead of shrink.

  • I Smell A Rat, er, A Blog Wednesday, 7 Oct 2009 | 2:31 PM ET

    I’ve said it before, and I know it’s a bad cliché (is there such a thing as a good cliché?), but I learn something new almost every day. Today, my lesson came in the form of an eye-catching research note out of Leerink Swann, which specializes in covering healthcare-related companies and stocks.

  • Novartis' Flu Shot Across The Bow Tuesday, 6 Oct 2009 | 1:23 PM ET
    Pharmacist wearing face mask

    Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.

  • Swine Flu By Any Other Name ... Like H1N1 Tuesday, 6 Oct 2009 | 12:59 PM ET

    The pork industry would prefer the media to use the more scientific term but "swine flu" tends to be more reader/viewer friendly.

  • Just Another Manic Monday In Biopharma Monday, 5 Oct 2009 | 11:36 AM ET

    If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.

  • A Race in Cardiology Thursday, 1 Oct 2009 | 1:06 PM ET
    Heart Drawing

    A race is on to develop the potentially next big thing in heart surgery: a replacement valve that can be implanted through thin tubes known as catheters rather than by traditional open-heart surgery.

  • Flu Fears Mean 24/7 Production for Mask Makers Wednesday, 30 Sep 2009 | 9:54 AM ET

    Workers are fighting the flu around the clock at the Alpha Pro Tech factory in Salt Lake City, Utah.

  • H1N1 Vaccine Is Top Flu Concern For U.S. Businesses Wednesday, 30 Sep 2009 | 7:36 AM ET
    New York Public Information Campaign Warns of Swine Flu

    The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.

  • Sequenom Board To CEO: "You're Fired" Tuesday, 29 Sep 2009 | 11:32 AM ET
    Sequenom

    It's the equivalent of slipping a press release with negative news under the door at the close of business on a Friday. But after the closing bell on Yom Kippur, when many people including me were trying to give up food and tweeting for a day, Sequenom tossed a grenade.

  • Dendreon Makes The List...Again Friday, 25 Sep 2009 | 12:44 PM ET

    2,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.

  • Do Drugs And Tweets Mix? Wednesday, 23 Sep 2009 | 2:50 PM ET
    Twitter

    The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.

  • The Jury's Out On Dendreon Tuesday, 22 Sep 2009 | 10:41 AM ET

    It's my turn. As fate would have it, on the day of Dendreon's first analyst/investor meeting in years, I have to report for jury duty this Thursday in Newark, NJ. But apparently it wouldn't have mattered if I were available anyway or wanted to send a surrogate.